The department of veterans affairs' unique clinical cancer research effort
- 1 November 1994
- Vol. 74 (S9) , 2701-2709
- https://doi.org/10.1002/1097-0142(19941101)74:9+<2701::aid-cncr2820741820>3.0.co;2-h
Abstract
Without organized clinical trials, we are doomed to repeat our mistakes endlessly. There are many genuine conflicts of interest intrinsic to clinical research. Some of these arise from the necessity of admitting that we as physicians do not know the best way to treat every disease or each patient and that all treatments currently available for this patient's disease are suboptimal. With humility and honesty, these conflicts of interest can be overcome. Surmounting other more palpable ones, however, is equally challenging. Supporting the participation of our patients in clinical trials requires a practical reconfiguration of practice patterns, different and more record keeping, and the surrender of autonomy. Each of these facts has economic implications. Practitioners who are paid according to the specific services they provide risk both significant income loss and cost increase by participating in clinical trials. The Department of Veterans Affairs is a charter member of the cancer clinical trials establishment and the originator of a long string of important firsts in cancer research. The nature of the VA system eliminates or diminishes the impact of many of the conflicts of interest that hinder clinical trial participation. This globally budgeted comprehensive system, which theoretically is responsible for the care of more citizens than is the entire Canadian national health service, is an unique clinical research resource. Some of the high points of the VA contributions to cancer treatment development are listed in this paper. Hopefully, this overview makes the point that the VA clinical research enterprise is a treasure that can ask critical questions that, because of irresolvable economic conflicts of interest, can be asked neither in the fee-for-service nor the prepaid health maintenance settings. This clinical cancer research resource must be nurtured and supported, and it must continue to address critical questions that it alone can answer.Keywords
This publication has 21 references indexed in Scilit:
- Effectiveness of salvage neck dissection for advanced regional metastases when induction chemotherapy and radiation are used for organ preservationThe Laryngoscope, 1992
- Prognostic significance of blood coagulation tests in carcinoma of the lung and colonBlood Coagulation & Fibrinolysis, 1992
- Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal CancerNew England Journal of Medicine, 1991
- Chronic Calcium Antagonist Use in Carcinoma of the Lung and Colon: A Retrospective Cohort Observational StudyCancer Investigation, 1990
- Effect of Mopidamol on Survival in Carcinoma of the Lung and Colon: Final Report of Veterans Administration Cooperative Study No. 188JNCI Journal of the National Cancer Institute, 1988
- Comparison of local versus central tumor measurements in a multicenter cancer trialAmerican Journal of Clinical Oncology, 1984
- Accrual of patients into a multihospital cancer clinical trial and its implications on planning future studiesAmerican Journal of Clinical Oncology, 1984
- Rapid and sensitive method for the determination of salicylic acid in serum by reversed-phase ion-pair high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1983
- Nursing assessment of the ambulatory patient with brain metastasesCancer Nursing, 1981
- Comparison of high-performance liquid chromatography and a spectrophotometric technique for determining plasma warfarinJournal of Chromatography B: Biomedical Sciences and Applications, 1978